Levels of Main Platelet Thrombin Receptors in Older Chronic Haemodialysis Patients.
Yan Li,Lin Shen,Rui Chen,Fanghong Lu,Jing Li,Jianguo Liu
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2010.17.041
2010-01-01
Abstract:To the Editor: We read with great interest the article by Yu et al,1 in which they summarized the recent progress and prospects of patients with kidney disease in China. This is a very interesting paper on kidney disease since the treatment of end-stage renal disease, especially the right time to haemodialysis (HD), has been controversial over the past decades. The prevalence of uremia is very high in old people in the general population.1 HD is one of the limited choices for the treatment of such end-stage renal disease. However, patients with uremia undergoing HD always have multiple comorbidities,2 such as cardiovascular diseases, which is a significant cause of mortality in these patients.3 Recent evidence showed that platelet dysfunction, especially the changed levels of platelet thrombin receptors, might be one of the main reasons for these comorbid conditions.4 Moal et al4 reported several platelet surface glycoproteins impaired in uraemic HD patients, however, other main platelet thrombin receptors such as proteinase activated receptor-1 (PAR1), proteinase activated receptor-4 (PAR4) and glycoprotein Ibα (GPIbα) have not been discussed. Participants in our study included 26 patients receiving chronic HD with a mean age of (72±11) years, and 27 control subjects with a mean age of (69±7) years. No significant differences were found in age and sex distribution. The HD patients had received routine chronic maintenance HD for more than 6 months (mean, (39±10) months). Their current hemorrhagic symptoms were recorded. Flow cytomery was used to assess the expression of PAR1, PAR4 and GPIbα levels on the platelet surface. The measurement of platelet thrombin receptors was carried out according to the literature.4 GPIbα level was expressed as mean fluorescence intensity (MFI), and 10 000 platelets were measured in each sample. PAR1 and PAR4 were expressed as percentage of the total platelet count. Platelet reactivity was assessed by ADP-stimulated aggregation. The results were expressed as the maximal platelet aggregation rate (MAR). The reagents and instruments were anti-GPIbα monoclonal antibody (Biolegend, USA), anti-PAR1 monoclonal antibody and anti-PAR4 monoclonal antibody (R&D, USA), fluorescein isothiocyanate (FITC)-conjugated rabbit polyclonal anti-goat IgG (Boster, China), LSR II flow cytometer (Becton-Dickison, USA), platelet aggregation inducer adenosine diphosphate (Sigma, USA), and a platelet aggregometer from Chronolog (USA). Data were expressed as mean±standard deviation. Comparisons between two groups were performed by Student's t test. The difference was considered significantly when the P value less than 0.05. Univariate analysis was performed using Pearson's correlation. The percentage of subjects with bleeding was significantly higher in the HD group than among the controls (23% vs. 4%, P=0.002). The expression of GPIbα was lower on the surface of platelets in elderly HD patients (116.8±25.6) than in control subjects (126.0±17.0), however, the difference was not statistically significant. The PAR1 percentage was higher in elderly HD patients compared with control subjects (24.6±14.5 vs. 8.2±4.0, P <0.001). PAR4 expression was a little higher in HD patients than in control subjects but not statistically significant. In the HD group, there was a positive relationship between PAR1 levels and the months of HD (r=0.601, P=0.001, Figure). The platelet MAR (%) in the HD group was (43.72±9.28), which was significantly lower than in the control subjects (54.86±15.82, P <0.01).Figure.: A positive correlation was found between PAR1 levels and the months of haemodialysis in the HD group.In this study, we found lower GPIbα, MAR and higher PAR1 in elderly HD patients and the positive correlation between PAR1 and HD frequency. GPIbα, a component of the GPIb/IX/V complex, is reported to be the high affinity binding site for both of thrombin and vWF.5 Qin et al6 reported that the expression of GPIbα in chronic renal failure (CRF) patients was decreased; this leads to platelet aggregation dysfunction, and might be one of the reasons for the hemorrhagic trend in CRF. In our study, although the lower expression of GPIbα in HD patients compared with controls was not significant, the platelet MAR was markedly lower in the elderly HD patients than in the controls, which was, in part, accordant with previous study; the difference might be because of the insufficient sample. PAR1 is a high-affinity receptor for the platelet activation of thrombin, and its values were higher in HD patients than in controls. In the study, we found an association between the high PAR1 level and the treatment course of HD. First, the malfunction of platelets in uremia patients was partly due to the toxins, urea, serum creatinine and guanidines, etc., therefore, dialysis decreases toxins and might up-regulate the expression of PAR1 on platelet membrane, although it did not improve platelet abnormalities. Second, the elevated platelet PAR1 levels in HD patients might be a defect in translocation, since cytoskeleton abnormalities have been reported in dialysis,7 and platelet PAR1 and the membrane skeleton are linked. HD can lead to abnormalities through the continuous platelet activation and repeated platelet stress induced by the interaction between blood and the artificial surfaces. HD accelerates atherosclerosis,8 and cardiovascular and cerebrovascular events account for the most of excess death rate seen in elderly HD patients.9 The presence of a high PAR1 level and more cardiovascular and cerebrovascular events in the HD group may indicate that the increase of platelet PAR1 level is a risk marker in HD patients. According to our findings, if a high PAR1 level is a reliable risk marker, and even a therapeutic target among elderly HD patients, the frequency of HD should be strictly controlled. Emphasis should be placed on early detection and implementation to slow the progression of CRF.1 These results reinforce the argument that predialysis care of older renal failure patients should be improved to achieve better conditions when starting dialysis.3 This study was supported by a grant from the National Natural Science Foundation of China (No. 30572441).